IP Library Granted Patent US 8,173,625
Granted Patent B2
US 8,173,625 · App. 12/437,735 · Granted May 8, 2012

Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine

Assignee: Theaprin Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,173,625
App. No.
12/437,735
Granted
May 8, 2012
Kind
B2
Abstract

A water-soluble aspirin-theanine cocrystal composition which includes a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer associated with the quantity of acetylsalicylic acid. The composition may be created by a method including the steps of: (i) providing a quantity of acetylsalicylic acid; (ii) adding a quantity of a theanine enantiomer to the quantity of acetylsalicylic acid to form a mixture comprising the quantity of acetylsalicylic acid and the enantiomer of theanine; (iii) wetting the mixture; and (iv) grinding the mixture for a length of time sufficient to produce a dried crystalline mass. The water-soluble cocrystal composition is suitable for intravenous administration, preferably to humans.

Claims (14)

1. A method of making a parenteral fluid, comprising the steps of:

providing a quantity of acetylsalicylic acid;

adding a quantity of L-theanine to said quantity of acetylsalicylic acid to form a mixture comprising said quantity of acetylsalicylic acid and said quantity of L-theanine;

dissolving said mixture in a quantity of a first solvent to form a solution;

drying said solution for a length of time sufficient to produce a dried crystalline mass of an acetylsalicylic acid-theanine cocrystal composition;

dissolving said dried crystalline mass in a second solvent to form an acetylsalicylic acid -theanine cocrystal solution; and

adding said acetylsalicylic acid-theanine cocrystal solution to an infusion fluid.

2. The method of claim 1 , wherein the infusion fluid is selected from the group consisting of D5W, D10W, D50, D5 0.3% NS, D5 0.45% NS, 0.45% NS, D5 0.9% NS, 0.9% NS, 3% NaCl, D5RL, LR, and NaHCO 3 .

3. The method of claim 1 , wherein said dried crystalline mass has an aqueous solubility of at least about 9.4 mg/mL.

4. The method of claim 1 , further comprising adding a sugar alcohol to said solution.

5. The method of claim 4 , wherein said sugar alcohol has an L-configuration.

6. The method of claim 1 , wherein said first solvent is water.

7. The method of claim 1 , wherein said second solvent is water.

8. The method of claim 1 , wherein the pH of said acetylsalicylic acid-theanine cocrystal solution is physiologic.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 027675 FRAME 0408. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECTIVE ASSIGNMENT OF A CHANGE OF NAME. Recorded Apr 6, 2012
From: SOLUPRIN PHARMACEUTICALS, INC.
To: THEAPRIN PHARMACEUTICALS INC.
Reel/Frame 028003/0601 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 027655 FRAME 0352. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 8, 2012
From: SOLUPRIN PHARMACEUTICALS, INC.
To: THERAPRIN PHARMACEUTICALS INC.
Reel/Frame 027675/0408 →
CHANGE OF NAME Recorded Feb 6, 2012
From: SOLUPRIN PHARMACEUTICALS, INC.
To: THEAPRIN PHARMACEUTICALS INC.
Reel/Frame 027655/0352 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2009
From: BRITTAIN, PHD, HARRY G.; FELICE, M.D., PHILIP V.
To: SOLUPRIN PHARMACEUTICALS, INC.
Reel/Frame 022673/0701 →
Continuity (1)
Related Publication 20100286099A1 · Nov 11, 2010